Transmembrane proteins in cancer: insights from mechanism to clinical impact
Open Biology · 2026
DOI: 10.1098/rsob.250259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Open Biology, 2026. Verfasst von Chih-Wen Shu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung80424, Taiwan. Hauptthemen laut MEDLINE: Neoplasms, Membrane Proteins. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Center for Cancer Research in Kaohsiung Medical University, the Kaohsiung Medical University Research Foundation, the NSYSU-KMU Joint Research Project.
Abstract (Originalsprache)
Transmembrane proteins (TMEMs) constitute a large family of proteins that span biological membranes and are distributed across various cellular organelles, playing key roles in maintaining cellular homeostasis. Increasing evidence has revealed that dysregulation of TMEMs is closely associated with cancer development and progression. Therefore, a deeper understanding of the relationship between TMEMs and cancer is essential. Different TMEMs can function either as oncogenes or tumour suppressors, depending on the context. In this review, we explore the involvement of TMEMs in cancer, categorizing them into three groups based on their roles: oncogenic, tumour-suppressive or dual-function (both oncogenic and tumour-suppressive). We summarize the roles of various TMEMs in different cancer types, highlighting both well-characterized proteins and those identified through database screening, even if their exact molecular mechanisms remain unclear. Where possible, we include known signalling pathways associated with these TMEMs. This review highlights the critical roles of the TMEM protein family and encourages further research into their mechanisms, prognostic value and potential as targets for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung80424, Taiwan.
- Innovation Center for Drug Development and Optimization, National Sun Yat-sen University , Kaohsiung, Taiwan.
- Department of Biomedical Science and Environmental Biology, College of Life Science, Kaohsiung Medical University, Kaohsiung80708, Taiwan.
- Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung80708, Taiwan.
- Center for Cancer Research, Kaohsiung Medical University, Kaohsiung80708, Taiwan.
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung80424, Taiwan.
ORCID-Profile: Chih-Wen Shu, Pei-Feng Liu, Yung-Fu Chang
Förderung
- the Center for Cancer Research in Kaohsiung Medical University
- the Kaohsiung Medical University Research Foundation
- the NSYSU-KMU Joint Research Project
- the Research Center for Molecular Medicine in Kaohsiung Medical University
- the Center for Precision Medicine in Kaohsiung Medical University
- the Ministry of Science and Technology of Taiwan
Zitieren
APA
Shu, C. W., Chang, C. H., Wang, H. H., Liu, P. F., & Chang, Y. F. (2026). Transmembrane proteins in cancer: insights from mechanism to clinical impact. Open Biology. https://doi.org/10.1098/rsob.250259
Vancouver
Shu CW, Chang CH, Wang HH, Liu PF, Chang YF. Transmembrane proteins in cancer: insights from mechanism to clinical impact. Open Biology. 2026. doi:10.1098/rsob.250259
BibTeX
@article{Shu2026,
author = {Shu, Chih-Wen and Chang, Chia-Hsuan and Wang, Hsing-Hsiang and Liu, Pei-Feng and Chang, Yung-Fu},
title = {Transmembrane proteins in cancer: insights from mechanism to clinical impact},
journal = {Open Biology},
year = {2026},
doi = {10.1098/rsob.250259}
}
EUVIMED